Liquid biopsies have shown great promise in the clinical management of cancer patients.
Despite considerable advances in molecular profiling, there remains a high unmet medical need for early cancer detection. The analysis of cell-free DNA (cfDNA) presents new opportunities to analyze low-expression biomarkers due to the high signal-to-noise ratio; to detect cancer early; to distinguish cancer from benign conditions; and to identify fast- and slow-growing cancers.
Liquid biopsy markers are advantageous because they can be used to assess overall prognosis, response to therapy, and likelihood of relapse or progression. This insightful whitepaper summarizes four peer-reviewed articles that explore the combination of exosomal RNA (exoRNA) and cfDNA in cancer diagnosis and treatment.
Offered Free by: Bio-Techne
See All Resources from: Bio-Techne
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.